Atezolizumab FDA approval date

The FDA approved Atezolizumab (Tecentriq) on 18 May 2016.

FDA approval date
18 May 2016

Drug identity checked against registry records

Also recorded as Tecentriq; Tecentriq (Brand name); Tecentriq®

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791ExelixisPhase 3Active not recruiting2021-11-30Actual
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940ExelixisPhase 3Active not recruiting2026-06-16Actual
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059NVCRPhase 2Completed2025-11-18Actual
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598Replimune, Inc.Phase 2Recruiting2027-12-01Estimated
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258Tempest TherapeuticsPhase 3Not yet recruiting2028-12Estimated
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574ExelixisPhase 3Enrolling by invitation2030-05-31Estimated
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117ExelixisPhase 3Active not recruiting2024-04-19Actual
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861CHRSPhase 2Terminated2025-06-30Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2016-05-18DayAtezolizumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761034", "applicant_as_listed_by_fda": "GENENTECH INC", "brand_names": ["TECENTRIQ"], "active_ingredients": ["ATEZOLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160518", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026